Prognostic and Clinicopathological Significance of Centrosomal Protein 55 in Different Cancers: A Meta and Bioinformatic Analysis

Abstract

Background: Centrosomal protein 55 (Cep55) is a mitogenic phosphoprotein that moves from the centrosome to the midbody of the cell and contributes to dislodging during late mitosis. It cooperates with the constituents of the intrasomal sorting complex, extracts the endosomal sorting complex required for transport (ESCRT) machinery, and promotes intercellular bridges contraction. Many studies have claimed an association between Cep55 expression and clinical performance prognosis. To verify this claim, a meta-analysis and bioinformatics analysis was performed to assess Cep55 prognostic and clinicopathological significance. Objective: The purpose of this study was to determine Cep55 prognostic value in neoplasms by analyzing the relationship between its expression and neoplasia patients clinico-prognosis. Methods: A meta-analysis and bioinformatics analysis was performed. Relevant studies were extracted from Pubmed, Embase, Cochrane Library, Web of Science, TCGA (The Cancer Genome Atlas) and GEO (Gene Expression Omnibus) databases using an appropriate search strategy. Quality of studies was evaluated by Newcastle-Ottawa Quality Weighted Assessment Scale (NOS). Meta-analysis was performed using the Stata 15.1 MP (multiprocessor) software (StataCorp company, College Station, TX, USA). Next, bioinformatics analysis was conducted to evaluate Cep55 expression in cancer patients. Cep55 expression data were retrieved from the Oncomine and GEPIA2 (Gene Expression Profiling Interactive Analysis 2) databases to compare Cep55 expression in dissimilar types of cancer and their relative health counterparts. Moreover, the association between Cep55 expression and the outcome of different carcinomas was evaluated. Results: A total of 11 studies involving 1535 cancer patients were included in the meta-analysis. Survival analysis showed that high Cep55 expression was associated with poor overall survival in patients with cancer (hazard ratio (HR): 1.58, 95% CI (confidence interval): 1.28–1.95, I² = 0%, p = 0.589). Bioinformatic analyses indicated that high Cep55 expression was associated with prognosis in patients with different tumors. Conclusions: Cep55 may be used as a potential prognostic biomarker for the identification of patients with tumors.